{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:36:42Z","timestamp":1784306202342,"version":"3.55.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jocn.2025.111114","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T15:43:58Z","timestamp":1739807038000},"page":"111114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Clinical and imaging features and treatment response of anti-NMDAR encephalitis combined with MOGAD"],"prefix":"10.1016","volume":"135","author":[{"given":"Guanhua","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Cai","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huabing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jocn.2025.111114_b0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ana.21050","article-title":"Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma","volume":"61","author":"Dalmau","year":"2007","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.jocn.2025.111114_b0010","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/jamaneurol.2013.4580","article-title":"Herpes simplex encephalitis as a potential cause of anti-N-methyl-D-aspartate receptor antibody encephalitis: report of 2 cases","volume":"71","author":"Desena","year":"2014","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.jocn.2025.111114_b0015","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.jocn.2025.111114_b0020","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","article-title":"The spectrum of MOG autoantibody-associated demyelinating diseases","volume":"9","author":"Reindl","year":"2013","journal-title":"Nat Rev Neurol"},{"issue":"22","key":"10.1016\/j.jocn.2025.111114_b0025","doi-asserted-by":"crossref","first-page":"e2302-e10","DOI":"10.1212\/WNL.0000000000009239","article-title":"Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies","volume":"94","author":"Martinez-Hernandez","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2025.111114_b0030","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.639265","article-title":"Case report: anti-NMDAR encephalitis with anti-MOG CNS demyelination after recurrent CNS demyelination","volume":"12","author":"Ren","year":"2021","journal-title":"Front Neurol"},{"issue":"3","key":"10.1016\/j.jocn.2025.111114_b0035","doi-asserted-by":"crossref","first-page":"82","DOI":"10.31083\/j.jin2103082","article-title":"Relapsing MOG-IgG-associated diseases coexisting with anti-NMDAR encephalitis: a case report and literature review","volume":"21","author":"Wang","year":"2022","journal-title":"J Integr Neurosci"},{"issue":"5","key":"10.1016\/j.jocn.2025.111114_b0040","doi-asserted-by":"crossref","first-page":"774","DOI":"10.4103\/aian.aian_236_23","article-title":"Ofatumumab, a fully human anti-CD20 monoclonal antibody, in the treatment of severe refractory anti-N-methyl-D-aspartate receptor encephalitis: two case reports","volume":"26","author":"Xue","year":"2023","journal-title":"Ann Indian Acad Neurol"},{"issue":"1","key":"10.1016\/j.jocn.2025.111114_b0045","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1186\/s12883-022-02974-x","article-title":"Anti-NMDA receptor encephalitis and MOG-associated demyelination - a case report with long-term follow-up and a systematic review","volume":"22","author":"Berek","year":"2022","journal-title":"BMC Neurol"},{"issue":"1","key":"10.1016\/j.jocn.2025.111114_b0050","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuroinflammation"},{"issue":"3","key":"10.1016\/j.jocn.2025.111114_b0055","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.jocn.2025.111114_b0060","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1474-4422(19)30488-0","article-title":"Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study","volume":"19","author":"Armangue","year":"2020","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.jocn.2025.111114_b0065","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.jocn.2025.111114_b0070","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.jocn.2025.111114_b0075","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.42780","article-title":"Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease in the United Kingdom","volume":"5","author":"Satukijchai","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jocn.2025.111114_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577987","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: presentation and outcomes of adults at a single center","volume":"373","author":"Sutton","year":"2022","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.jocn.2025.111114_b0085","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000633","article-title":"Anti-NMDAR encephalitis: a single-center, longitudinal study in China","volume":"7","author":"Xu","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10","key":"10.1016\/j.jocn.2025.111114_b0090","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1212\/WNL.0b013e31822cfc6b","article-title":"Analysis of relapses in anti-NMDAR encephalitis","volume":"77","author":"Gabilondo","year":"2011","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jocn.2025.111114_b0095","doi-asserted-by":"crossref","first-page":"e1095","DOI":"10.1212\/WNL.0000000000201662","article-title":"Significance of myelin oligodendrocyte glycoprotein antibodies in CSF: a retrospective multicenter study","volume":"100","author":"Carta","year":"2023","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jocn.2025.111114_b0100","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1093\/brain\/awad122","article-title":"Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids","volume":"146","author":"Matsumoto","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.jocn.2025.111114_b0105","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.msard.2018.01.007","article-title":"Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis","volume":"20","author":"Fan","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.jocn.2025.111114_b0110","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/ane.13568","article-title":"Relapse factors of patients of anti-N-methyl-D-aspartate receptor encephalitis","volume":"145","author":"Zhao","year":"2022","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jocn.2025.111114_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.832634","article-title":"Recurrence of anti-N-methyl-D-aspartate receptor encephalitis: a cohort study in Central China","volume":"13","author":"Feng","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.jocn.2025.111114_b0120","article-title":"Relapses of anti-NMDAR, anti-GABABR and anti-LGI1 encephalitis: a retrospective cohort study","volume":"13","author":"Zhong","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jocn.2025.111114_b0125","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1212\/NXI.0000000000000322","article-title":"MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy","volume":"4","author":"Ogawa","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1016\/j.jocn.2025.111114_b0130","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/jnnp-2016-315094","article-title":"Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies","volume":"88","author":"Fujimori","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2025.111114_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.600169","article-title":"Clinical and radiological features of adult onset bilateral medial frontal cerebral cortical encephalitis with anti-myelin oligodendrocyte glycoprotein antibody","volume":"11","author":"Fujimori","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.jocn.2025.111114_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102011","article-title":"Seizures and myelin oligodendrocyte glycoprotein (MOG) antibodies: two paradigmatic cases and a review of the literature","volume":"41","author":"Foiadelli","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.jocn.2025.111114_b0145","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e318228c136","article-title":"Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis","volume":"77","author":"Martinez-Hernandez","year":"2011","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jocn.2025.111114_b0150","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/jnnp-2020-325302","article-title":"Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management","volume":"92","author":"Abboud","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.1016\/j.jocn.2025.111114_b0155","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamaneurol.2021.3188","article-title":"Use and safety of immunotherapeutic management of N-methyl-d-aspartate receptor antibody encephalitis: a meta-analysis","volume":"78","author":"Nosadini","year":"2021","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.jocn.2025.111114_b0160","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001088","article-title":"Rituximab treatment and long-term outcome of patients with autoimmune encephalitis: real-world evidence from the GENERATE registry","volume":"8","author":"Thaler","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.jocn.2025.111114_b0165","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.jocn.2025.111114_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104571","article-title":"Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"72","author":"Chang","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/j.jocn.2025.111114_b0175","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/13524585241226830","article-title":"Effectiveness of immunotherapies in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"30","author":"Bilodeau","year":"2024","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.jocn.2025.111114_b0180","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1474-4422(10)70253-2","article-title":"Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis","volume":"10","author":"Dalmau","year":"2011","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.jocn.2025.111114_b0185","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ana.24117","article-title":"Overlapping demyelinating syndromes and anti\u2013N-methyl-D-aspartate receptor encephalitis","volume":"75","author":"Titulaer","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2025.111114_b0190","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jocn.2025.111114_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120394","article-title":"A single low-dose rituximab infusion in severe chronic refractory myasthenia gravis in resource-limited settings","volume":"442","author":"Heckmann","year":"2022","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.jocn.2025.111114_b0200","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12974-022-02622-8","article-title":"Simplified regimen of combined low-dose rituximab for autoimmune encephalitis with neuronal surface antibodies","volume":"19","author":"Du","year":"2022","journal-title":"J Neuroinflammation"},{"issue":"8","key":"10.1016\/j.jocn.2025.111114_b0205","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1111\/ene.15355","article-title":"Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder","volume":"29","author":"Huang","year":"2022","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2025.111114_b0210","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1439899","article-title":"Efficacy and safety of low-dose rituximab in the treatment of myasthenia gravis: a systemic review and meta-analysis","volume":"15","author":"Yang","year":"2024","journal-title":"Front Neurol"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586825000864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586825000864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T14:39:02Z","timestamp":1755095942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586825000864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":42,"alternative-id":["S0967586825000864"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2025.111114","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and imaging features and treatment response of anti-NMDAR encephalitis combined with MOGAD","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2025.111114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"111114"}}